Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA), an emerging growth company incorporated in Florida, filed this Form 8-K on September 17, 2026. The report discloses a material development regarding the Company's clinical trial program for its product candidate Ketamir-2.
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on regulatory and clinical developments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The primary material event reported is the advancement of the Phase 2a clinical program evaluating Ketamir-2 for chemotherapy-induced peripheral neuropathy (CIPN). Following a review of the study protocol by the U.S. Food and Drug Administration (FDA), the Company incorporated FDA feedback and submitted the revised protocol for Institutional Review Board (IRB) review at a leading cancer research institution. The program has advanced toward site initiation.
Guidance, Outlook, and Risks
The filing includes a standard cautionary note regarding forward-looking statements. Management commentary is limited to the status of the Ketamir-2 trial. The Company highlights significant risks and uncertainties, including:
- Preclinical and clinical development outcomes.
- Ability to obtain regulatory approvals.
- Reliance on third parties.
- Intellectual property protection.
- Financing needs.
The Company explicitly states it undertakes no obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Confirm the status of the Institutional Review Board (IRB) approval for the Ketamir-2 Phase 2a protocol.
- Verify the specific timeline for site initiation and patient enrollment.
- Review the Company's most recent Form 10-K or 10-Q for current cash runway and financing needs, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on the FDA's feedback or changes to the study design.